T. Rowe Price Health Care ETFTMED

The T. Rowe Price Health Care ETF (TMED) ended last week with a market capitalisation of $4.5 billion, reflecting a year-to-date return of 13.5%. The fund’s most recent prospectus highlights its focus on the health care sector, with significant allocations to pharmaceuticals, biotechnology, and health care providers. The fund’s top holdings include UnitedHealth Group, Merck, and Eli Lilly, which together account for nearly 20% of the portfolio.

The ETF’s mandate is to provide investors with exposure to the health care sector, which includes pharmaceuticals, biotechnology, and health care providers. The fund holds a diversified portfolio of health care stocks, with its top ten holdings making up approximately 40% of the total assets. This concentration in a few large-cap stocks means that the fund’s performance is heavily influenced by these key players.

The fund charges an expense ratio of 0.75%, which is slightly higher than the average for health care ETFs. This fee covers the costs of managing the fund, including administrative expenses and the fund manager’s fees. The fund’s tracking error of 0.12% indicates that it closely follows the performance of its benchmark index, the MSCI USA IMI Health Care 25/50 Index.

According to data from Nasdaq, TMED has seen steady trading volumes, with an average daily volume of around 100,000 shares. This liquidity makes it relatively easy for investors to buy and sell shares in the fund. The fund’s largest holdings are all well-established companies with strong market positions, which contributes to the fund’s stability.

However, the fund’s reliance on a few key stocks means that any downturn in the performance of these companies could have a significant impact on the fund’s overall returns. also, the health care sector is subject to regulatory risks, including changes in government policies and pricing pressures from insurance companies and healthcare providers.

The fund’s prospectus and other regulatory filings can be found on the SEC’s EDGAR database, providing investors with detailed information about the fund’s holdings and performance. For those looking to analyse the fund’s fees, the FINRA Fund Analyzer is a useful tool that breaks down the costs of investing in TMED.